Abbott Laboratories (NYSE:ABT) Shares Sold by Livingston Group Asset Management CO operating as Southport Capital Management

Livingston Group Asset Management CO operating as Southport Capital Management trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 33.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,596 shares of the healthcare product maker’s stock after selling 1,845 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Abbott Laboratories were worth $312,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ABT. United Bank increased its position in shares of Abbott Laboratories by 4.0% in the 2nd quarter. United Bank now owns 30,492 shares of the healthcare product maker’s stock worth $2,564,000 after purchasing an additional 1,166 shares during the last quarter. Kanawha Capital Management LLC increased its position in shares of Abbott Laboratories by 0.4% in the 2nd quarter. Kanawha Capital Management LLC now owns 169,929 shares of the healthcare product maker’s stock worth $14,291,000 after purchasing an additional 740 shares during the last quarter. Schroder Investment Management Group increased its position in shares of Abbott Laboratories by 4.0% in the 2nd quarter. Schroder Investment Management Group now owns 721,774 shares of the healthcare product maker’s stock worth $60,701,000 after purchasing an additional 27,688 shares during the last quarter. Gladstone Institutional Advisory LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter worth about $201,000. Finally, First Foundation Advisors increased its position in shares of Abbott Laboratories by 13.3% in the 2nd quarter. First Foundation Advisors now owns 6,660 shares of the healthcare product maker’s stock worth $560,000 after purchasing an additional 781 shares during the last quarter. 73.59% of the stock is owned by institutional investors.

Shares of NYSE:ABT opened at $88.28 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. Abbott Laboratories has a fifty-two week low of $68.80 and a fifty-two week high of $89.24. The firm has a 50-day simple moving average of $86.16 and a 200 day simple moving average of $84.59. The company has a market cap of $155.15 billion, a PE ratio of 30.65, a P/E/G ratio of 2.20 and a beta of 1.12.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 16th. The healthcare product maker reported $0.84 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.84. The firm had revenue of $8.08 billion during the quarter, compared to analyst estimates of $8.10 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. Abbott Laboratories’s revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 EPS. As a group, research analysts forecast that Abbott Laboratories will post 3.24 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 1.63%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.32. The ex-dividend date is Tuesday, January 14th. Abbott Laboratories’s payout ratio is presently 50.00%.

A number of equities research analysts recently weighed in on ABT shares. ValuEngine downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Credit Suisse Group boosted their price objective on shares of Abbott Laboratories from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. William Blair reaffirmed an “underperform” rating on shares of Abbott Laboratories in a research report on Thursday, October 17th. Citigroup downgraded shares of Abbott Laboratories from a “neutral” rating to a “sell” rating in a research report on Thursday, January 2nd. Finally, Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $91.42.

In other Abbott Laboratories news, SVP Randel William Woodgrift sold 21,000 shares of the business’s stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $80.54, for a total transaction of $1,691,340.00. Following the completion of the transaction, the senior vice president now directly owns 68,562 shares of the company’s stock, valued at approximately $5,521,983.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.70% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Read More: What is the Shanghai Stock Exchange Composite Index?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.